|
2016
|
Invention
|
Peptide scaffold design.
The present invention relates to novel peptides and methods for treatme... |
|
|
Invention
|
Dimeric scaffold peptides comprising hiv-1 gp120 and gp41 epitopes. The present invention relates... |
|
|
Invention
|
Dosage regimen for hiv vaccine.
The present invention relates to a novel dosage regimen in the t... |
|
|
Invention
|
Dosage regimen for hiv vaccine. The present invention relates to a novel dosage regimen in the tr... |
|
2015
|
Invention
|
Stabilized hiv-1 peptide constructs comprising the gp120 c5 domain and gp41 hydrophilic domain. D... |
|
|
Invention
|
Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) ... |
|
|
Invention
|
Method for reducing hiv-1 reservoir size using multivalent immunogen and reservoir purging agent.... |
|
|
Invention
|
Method for the vaccination against hiv. The present invention relates to novel compositions of ac... |
|
|
Invention
|
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine indu... |
|
|
Invention
|
Dosage regimen for hiv vaccine. The present invention relates to novel compositions of active age... |
|
2014
|
Invention
|
Hiv vaccine. The present invention relates to novel compositions of active agents and methods for... |
|
2013
|
Invention
|
Method for the vaccination against hiv. The present invention relates to methods for treating red... |
|
|
Invention
|
Vaccine.
The present invention relates to novel combinations of active agents and methods for tr... |
|
|
Invention
|
Peptides derived from viral proteins for use as immunogens and dosage reactants. The present inve... |
|
|
Invention
|
Method of inducing an anti-hiv-1 immune response comprising administering a c5/tm-gp41 peptide di... |
|
|
Invention
|
Vaccine. The present invention relates to novel combinations of active agents and methods for tre... |
|
|
Invention
|
Hiv vaccine. The present invention relates to novel combinations of active agents and methods for... |
|
2012
|
Invention
|
Dimeric scaffold proteins comprising hiv-1 gp120 and gp41 epitopes. 6 (formula I)
|
|
|
Invention
|
Monomeric and multimeric immunogenic peptides. The present invention relates to novel peptides an... |
|
2011
|
Invention
|
Peptide scaffold design. 5 (I)
|
|
|
Invention
|
Peptide scaffold design. The present invention relates to novel peptides and methods for treatmen... |
|
2010
|
Invention
|
Peptide constructs derived from the gp120 c5 domain and gp41 transmembrane domain. Disclosed is a... |
|
|
Invention
|
Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic me... |
|
2007
|
Invention
|
Method of producing an hiv-1 immune response. The present invention comprises novel and modified ... |
|
2005
|
Invention
|
Modified hiv peptides, antigens, compositions, immunoassay kit and a method of detecting antibodi... |
|
2002
|
Invention
|
Modified hiv-1gag p17 peptide and immunogenic composition. The present invention comprises novel ... |
|
2001
|
Invention
|
Hiv-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit. The prese... |
|
|
Invention
|
Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines. Th... |
|
|
Invention
|
Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine compone... |
|
2000
|
Invention
|
Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodie... |
